-
AI stock boom delivers bumper quarter for Japan's SoftBank
-
Asian stocks struggle as US shutdown rally loses steam
-
India probes deadly Delhi blast, vows those responsible will face justice
-
Pistons win streak hits seven on night of NBA thrillers
-
US state leaders take stage at UN climate summit -- without Trump
-
Burger King to enter China joint venture, plans to double stores
-
Iraqis vote in general election in rare moment of calm
-
Philippines digs out from Typhoon Fung-wong as death toll climbs to 18
-
'Demon Slayer' helps Sony hike profit forecasts
-
Who can qualify for 2026 World Cup in next round of European qualifiers
-
Ireland's climate battle is being fought in its fields
-
Sony hikes profit forecasts on strong gaming, anime sales
-
End to US government shutdown in sight as stopgap bill advances to House
-
'Western tech dominance fading' at Lisbon's Web Summit
-
Asian stocks rise as record US shutdown nears end
-
'Joy to beloved motherland': N.Korea football glory fuels propaganda
-
Taiwan coastguard faces China's might near frontline islands
-
Concentration of corporate power a 'huge' concern: UN rights chief
-
Indian forensic teams scour deadly Delhi car explosion
-
Trump says firebrand ally Greene has 'lost her way' after criticism
-
Show shines light on Mormons' unique place in US culture
-
Ukraine, China's critical mineral dominance, on agenda as G7 meets
-
AI agents open door to new hacking threats
-
Syria joins alliance against Islamic State after White House talks
-
As COP30 opens, urban Amazon residents swelter
-
NHL unveils new Zurich office as part of global push
-
Szalay wins Booker Prize for tortured tale of masculinity
-
Tocvan Announces Maiden Drill Program Underway at North Block Gran Pilar Gold-Silver Project
-
'Netflix House' marks streaming giant's first theme park
-
UN warns of rough winter ahead for refugees
-
Brazil's 'action agenda' at COP30 takes shape
-
Trump threatens $1 billion action as BBC apologises for edit error
-
Sinner dominates injury-hit Auger-Aliassime in ATP Finals opener
-
Trump hails Syria's 'tough' ex-jihadist president after historic talks
-
Syria's ex-jihadist president meets Trump for historic talks
-
Top US court hears case of Rastafarian whose hair was cut in prison
-
US mediator Kushner and Netanyahu discuss phase two of Gaza truce
-
End to US government shutdown in sight as Democrats quarrel
-
Trump threatens air traffic controllers over shutdown absences
-
US to remove warnings from menopause hormone therapy
-
UK water firm says 'highly likely' behind plastic pellet pollution incident
-
Syria's ex-jihadist president holds historic Trump talks
-
End to record-long US government shutdown in sight
-
France's ex-leader Sarkozy says after jail release 'truth will prevail'
-
Atalanta sack coach Juric after poor start to season
-
Trump threatens $1 billion action as BBC apologises for speech edit
-
Gattuso wants 'maximum commitment' as Italy's World Cup bid on the line
-
Indian capital car blast kills at least eight
-
Deadly measles surge sees Canada lose eradicated status
-
Brazil's Lula urges 'defeat' of climate deniers as COP30 opens
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
D.Moore--AMWN